Please Wait...

Bioclinica Announces Comprehensive COVID-19 Clinical Endpoint Adjudication Solution

May 7, 2020

PRINCETON, N.J., May 7, 2020 – Bioclinica, a leading provider of clinical science and technology expertise to assist the life science industry, today announced a specialized program for the adjudication of adverse events that could result from COVID-19 infection. Bioclinica's new program provides an out-of-the-box Clinical Endpoint Committee solution. This solution combines world-class medical expertise, an experienced adjudication management team, and a cutting-edge endpoint adjudication platform to help pharmaceutical and medical device researchers discern COVID-related adverse events from those not associated with COVID-19.

"For ongoing clinical trials that might be impacted by COVID-19, we recognize that time is of the essence. COVID-related maladies can significantly confound the safety analysis of ongoing clinical trials," said Dan Gebow, Ph.D., Senior Vice President of Research and Development at Bioclinica. "As a company founded and led by scientists, we understand the importance of having the best research tools at our fingertips – especially when adapting to a rapidly changing landscape as we are experiencing during this pandemic."

Bioclinica's COVID-19 Clinical Adjudication Solution is designed to quickly evaluate a clinical trial protocol and charter to determine if novel COVID endpoint adjudication pathways should be added. Researchers can elect to utilize Bioclinica's pre-programmed COVID Source Document collection system, COVID Adjudication Pathways, and expert adjudicators, or they can customize each component to best suit their trial.  

Bioclinica's expert physician adjudication network was formed in partnership with C. Michael Gibson, M.S., M.D. of Boston Clinical Research Institute (BCRI) and Harvard Medical School. The network consists of experienced adjudicators from Cardiology, Pulmonology, Neurology, Hepatology, Gastroenterology, and other specialties impacted by the deadly virus. 

"The COVID-19 pandemic has given rise to a new specialist, the 'Covidologists' who are adept at diagnosing and caring for a new constellation of inflammatory, infectious, and thrombotic complications affecting many organ systems," said Dr. Gibson.

"We felt we were in a unique position to assist our fellow researchers, as our team can offer adjudication services and cloud-based software under-one-roof," said Dr. Gebow.  "COVID-19 adds significant risk for pharmaceutical and medical device clinical trials by confounding important safety endpoints. Our solution minimizes that risk by eliminating the need to patch together various endpoint adjudication services, expertise, and software from multiple disparate sources."

Bioclinica's COVID-19 Adjudication Solution can be used as a standalone solution for new research studies or as an add-on to ongoing studies. Moreover, as new trials launch that specifically focus on COVID-19 detection, treatment, and surveillance, Bioclinica's COVID-19 Adjudication Solution efficiently facilitates adjudication of resulting adverse events. 

 

About Bioclinica

Bioclinica is a global life science provider that utilizes science and technology to bring clarity to clinical trials – helping companies to develop new life-improving therapies more efficiently and safely. The company's offerings include medical imaging and cardiac safety services; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site and patient payments and budget forecasting; pharmacovigilance, and trial management. The company's thousands of employees serve more than 500 pharmaceutical, biotechnology and device organizations – including all top 20 biopharmaceutical companies and leading CROs – through offices in North America, Europe, and Asia.

 

###

 

Media Contact
Nicole Klatsky
+1 (609) 865-5212
nicole.klatsky@bioclinica.com

 

 

Learn more about Bioclinica at www.Bioclinica.com and in the Bioclinica Blog. Follow the latest company news and happenings on LinkedIn and Twitter.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Clinical #datamanagement is essential to ensure high-quality data in #clinicaltrials, but the components are comple… https://t.co/klK81O6YA2
Bioclinica (16 hours ago)
Congratulations to Jeff Heilbraun, M.S., VP, Medical & Scientific Affairs, for his latest article on cardiovascular… https://t.co/JSuEaeQOYh
Bioclinica (5 days ago)
Changes are a fact of life - and of #clinicaltrial design. But planning and budgeting for your trial don’t have to… https://t.co/wsfMPAwLxR
Bioclinica (3 weeks ago)
Don't compromise with manual systems and spreadsheets. As an entry-level system with phased implementation, Bioclin… https://t.co/dYDJO4Qh7S
Bioclinica (3 weeks ago)
Our webinar on Neuroimaging in Parkinson’s Disease is tomorrow at 10:30 a.m. EDT. Register at:… https://t.co/4j0FGeXG0B
Bioclinica (3 weeks ago)
Today is World Ovarian Cancer Day. Ovarian cancer has the lowest survival rate of all female cancers. #Bioclinica p… https://t.co/1nMGahTMaz
Bioclinica (4 weeks ago)